These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 241531)

  • 1. Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease.
    Das KM; Eastwood MA
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 1):514-20. PubMed ID: 241531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine.
    Bates TR; Blumenthal HP; Pieniaszek HJ
    Clin Pharmacol Ther; 1977 Dec; 22(6):917-27. PubMed ID: 21768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acetylator phenotype and serum levels of sulfapyridine in patients with inflammatory bowel disease.
    Sharp ME; Wallace SM; Hindmarsh KW; Brown MA
    Eur J Clin Pharmacol; 1981; 21(3):243-50. PubMed ID: 6119205
    [No Abstract]   [Full Text] [Related]  

  • 4. Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease.
    Day JM; Houston JB
    Br J Clin Pharmacol; 1980 Jan; 9(1):91-4. PubMed ID: 6101957
    [No Abstract]   [Full Text] [Related]  

  • 5. Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis.
    Bondesen S; Nielsen OH; Schou JB; Jensen PH; Lassen LB; Binder V; Krasilnikoff PA; Danø P; Hansen SH; Rasmussen SN
    Scand J Gastroenterol; 1986 Aug; 21(6):693-700. PubMed ID: 2875518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.
    Klotz U; Maier K; Fischer C; Heinkel K
    N Engl J Med; 1980 Dec; 303(26):1499-502. PubMed ID: 6107853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulfasalazine metabolite pharmacokinetics in pediatric patients with inflammatory bowel disease: effects of disease activity, acetylator phenotype, and age.
    Clarke DF; George D; Milsap RL; Pogonowska-Wala E; Owerbach J; Lebenthal E; Jusko WJ
    Pediatr Pharmacol (New York); 1982; 2(4):323-33. PubMed ID: 6152489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulfapyridine metabolites in children with inflammatory bowel disease receiving sulfasalazine.
    Goldstein PD; Alpers DH; Keating JP
    J Pediatr; 1979 Oct; 95(4):638-40. PubMed ID: 39125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Estimations of the serum levels of sulfapyridine on patients treated with sulfasalazin (author's transl)].
    Eitner K; Hippius M; Reinicke C
    Dtsch Z Verdau Stoffwechselkr; 1982; 42(1):14-9. PubMed ID: 6122556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites.
    Järnerot G; Into-Malmberg MB; Esbjörner E
    Scand J Gastroenterol; 1981; 16(5):693-7. PubMed ID: 6119765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemolysis during salicylazosulfapyridine therapy.
    van Hees PA; van Elferen LW; van Rossum JM; van Tongeren JH
    Am J Gastroenterol; 1978 Nov; 70(5):501-5. PubMed ID: 33552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy of inflammatory bowel disease. Part 1. Sulfasalazine.
    Das KM
    Postgrad Med; 1983 Dec; 74(6):141-8, 150-1. PubMed ID: 6139795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug therapy of inflammatory bowel disease.
    Sack DM; Peppercorn MA
    Pharmacotherapy; 1983; 3(3):158-76. PubMed ID: 6136027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is plasma level monitoring of sulfasalazine indicated in the treatment of Crohn's disease or ulcerative colitis?
    Fischer C; Klotz U
    Ther Drug Monit; 1980; 2(2):153-8. PubMed ID: 6132473
    [No Abstract]   [Full Text] [Related]  

  • 15. Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases.
    Rahav G; Zylber-Katz E; Rachmilewitz D; Levy M
    Isr J Med Sci; 1990 Jan; 26(1):31-4. PubMed ID: 1968894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative pharmacokinetics of sulphasalazine and sulphapyridine after rectal and oral administration to patients with ulcerative colitis.
    Allgayer H; Kruis W; Eisenburg J; Paumgartner G
    Eur J Clin Pharmacol; 1984; 26(2):275-7. PubMed ID: 6144549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Determination of sulfapyridine levels in serum--a possibility for the control of dose related therapy with sulfasalazine].
    Eitner K; Reinicke C; Hippius M
    Dtsch Z Verdau Stoffwechselkr; 1984; 44(6):282-8. PubMed ID: 6151895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desensitization of patients with inflammatory bowel disease to sulfasalazine.
    Taffet SL; Das KM
    Am J Med; 1982 Oct; 73(4):520-4. PubMed ID: 6127032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Further studies of sulphasalazine metabolism in the treatment of ulcerative colitis.
    Cowan GO; Das KM; Eastwood MA
    Br Med J; 1977 Oct; 2(6094):1057-9. PubMed ID: 21720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.
    Das KM; Eastwood MA; McManus JP; Sircus W
    N Engl J Med; 1973 Sep; 289(10):491-5. PubMed ID: 4146729
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.